Related Experiment Video
Updated: Jun 8, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Methylprednisolone worsening neuropathic pain in non-traumatic thoracic myelopathy
1Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Neihu District, Taipei, Taiwan.
Abstract:
Methylprednisolone (MP) is the only neuroprotective medication currently in widespread use for the treatment of spinal cord injury. Increasingly, published studies challenge its clinical effects in view of its serious side-effects including wound infection, pneumonia, sepsis and steroid myopathy. Most cases with spontaneous spinal epidural haematoma (SSEH) need emergency evacuation, and typically show good neurologic recovery. Some patients with SSEH given preoperative or postoperative MP within hours of the onset of symptoms, and have had good motor recovery, although no mention was made of sensory function. Severe, intractable neuropathic pain has not been reported in patients with SSEH. We present a case of SSEH treated with a high-dose MP 16 h after onset of symptoms. Surgical decompression was performed 1 h after MP treatment. Motor recovery was good; however, intractable neuropathic pain developed 5 weeks postoperatively. We discuss the factors contributing to intractable pain. We speculate that the severe, intractable pain might be due to misuse of large-dose steroids in this case of non-traumatic spinal myelopathy, and not because of the injury per se.
Insights
Methylprednisolone (MP) may not improve outcomes for spontaneous spinal epidural hematoma (SSEH). High-dose MP treatment in this case was followed by severe neuropathic pain, suggesting potential steroid misuse.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Methylprednisolone (MP) is a common treatment for spinal cord injury, but its efficacy and side effects are debated.
- Spontaneous spinal epidural hematoma (SSEH) typically requires surgical decompression for good neurological recovery.
Observation:
- A patient with SSEH received high-dose MP 16 hours after symptom onset, followed by surgery.
- While motor function recovered well, the patient developed severe, intractable neuropathic pain 5 weeks post-surgery.
Findings:
- This case suggests that high-dose MP may not be beneficial and could potentially contribute to adverse outcomes like intractable pain in SSEH.
- The development of severe neuropathic pain was speculated to be linked to the timing and dosage of steroid administration.
Implications:
- Rethinking the use of MP in non-traumatic spinal myelopathy cases like SSEH is warranted.
- Further research is needed to understand the risks and benefits of MP in specific spinal cord injury contexts.
- Clinical guidelines for MP use in SSEH may need revision to prevent potential complications.
Related Concept Videos
Degenerative Disc Disease ll: Pathophysiology
Analgesia and Pain Management